Anqi Mirui (安琪米瑞)安琪米瑞
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 吉林津升制药有限公司Chinese legal name: 吉林津升制药有限公司
主要成分Active Ingredients
- 肌苷inosine
药物知识说明
肌苷是一种在国家药监局注册认定的药品。该药品含有肌苷-e3d74b2b等成分。
该药品关联的活性成分包括：肌苷inosine。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：吉林津升制药有限公司Chinese legal name: 吉林津升制药有限公司。
您可以探索含有相同成分的其他药品：肌苷-e3d74b2b成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 安琪米瑞) is a medicine registered with the national drug regulatory authority. It contains inosine as active ingredient(s).
Active ingredients associated with this product: 肌苷inosine.
Manufacturers recorded for this product: 吉林津升制药有限公司Chinese legal name: 吉林津升制药有限公司.
Explore other medicines containing the same ingredient: 肌苷 productsinosine products.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 安琪米瑞Recorded Chinese name: 安琪米瑞
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 0.2g0.2 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 吉林津升制药有限公司Chinese legal name: 吉林津升制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20050092
关联实体Relationships
相关问题Questions
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20050092
Manufacturer
Chinese legal name: 吉林津升制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
This section follows an NMPA labeling revision requirement. Any English text is a translation of the Chinese revision requirement for reference and is not an official English label.
Announcement: 2026 No. 87 2026-09-02
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
This section follows an NMPA labeling revision requirement. Any English text is a translation of the Chinese revision requirement for reference and is not an official English label.
Announcement: 2026 No. 87 2026-09-02
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20050092
生产企业
吉林津升制药有限公司(国产)
适应症
1.辅酶类药，具有改善机体代谢作用。|2.用于各种原因所致的白细胞减少和血小板减少、心力衰竭、心绞痛、肝炎等等辅助治疗。|3.可用于视神经萎缩、中心性视网膜炎的辅助治疗。
用法用量
用前稀释后，加入100ml 0.9% 氯化钠注射液或5%葡萄糖注射液中静脉滴注，一次0.2～0.6g((以肌苷计)，每日1～2次。
不良反应
已按国家药监局最新说明书修订要求更新 This section follows an NMPA labeling revision requirement. Any English text is a translation of the Chinese revision requirement for reference and is not an official English label.
修订要求来源Revision requirement source
- SOURCE 国家药品监督管理局SOURCE National Medical Products Administration
- EVIDENCE TYPE 说明书修订要求EVIDENCE TYPE labeling revision requirement
- 2026年第87号 2026-09-022026 No. 87 2026-09-02. Requirement text is not an official English label.
上市后监测到肌苷注射制剂以下药品不良反应/事件（这些不良反应/事件来自于无法确定样本量的自发报告，难以准确估计其发生频率）：
全身性疾病及给药部位各种反应：畏寒、寒战、发热、高热、胸闷、胸痛、乏力、疼痛、不适、肿胀、水肿、注射部位疼痛。
胃肠系统疾病：恶心、呕吐、腹痛、腹胀、腹泻、腹部不适、口干。
皮肤及皮下组织类疾病：皮疹（荨麻疹、斑丘疹、丘疹）、瘙痒、红斑、皮肤发红、皮肤变色、多汗。
血管与淋巴管类疾病：潮红、苍白、发绀、静脉炎、血压升高、血压下降。
各类神经系统疾病：头晕、头痛、震颤、麻木。
心脏器官疾病：心悸、心动过速、心律失常。
呼吸系统、胸及纵隔疾病：呼吸急促、呼吸困难、窒息感、咳嗽、哮喘。
免疫系统疾病：超敏反应、类过敏反应、过敏性休克。
各类损伤、中毒及操作并发症：输液相关反应。
精神病类：抽搐、烦躁不安、精神障碍。
各种肌肉骨骼及结缔组织疾病：背痛、肌痛。
禁忌
对本品过敏者禁用。
注意事项
1.本品静脉滴注有引起心脏骤停和过敏性休克死亡的报道，建议应用时缓慢滴注并严密观察生命指征变化及有无过敏反应。|2.需要限钠患者应慎用。|3.使用前应详细检查，如有下列情况之一者，请勿使用:|(1)药液浑浊。|(2)瓶身或瓶口有细微破裂。|(3)有棉絮状菌丝团。|(4)封口松动。
贮藏
遮光，密闭保存。
规格
0.2g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.